GMO CEO sees growing interest in liquid alternatives
‘I don’t have enough liquid alternatives on my platform’ – is a common confession from heads of manager research at different wealth platforms in Asia, according to GMO CEO Scott Hayward.
Latest news
-
GMO CEO sees growing interest in liquid alternatives
‘I don’t have enough liquid alternatives on my platform’ – is a common confession from heads of manager research at different wealth platforms in Asia, according to GMO CEO Scott Hayward.
-
UBS GWM launches EAM access fund programme for clients in Asia
The programme provides access to institutional quality investment opportunities through a selection of high-performing funds.
-
Barclays PB opens Singapore booking centre
The centre combines local booking capabilities in Singapore with connectivity to Barclays’ international booking centres.
-
JPMAM rebrands Campbell Global to J.P. Morgan Natural Capital
J.P. Morgan Natural Capital is part of J.P. Morgan Asset Management’s $326bn alternative investment business.
-
People Moves – August 2026
Here is a digest of significant wealth and asset management appointments, promotions and departures during the previous month.
-
3 biotech funds that more than doubled in 14 months
FSA highlights three actively managed biotechnology equity strategies that have more than doubled in value over the recent 14-month period.
Asset class in focus
-
Sponsored by Loomis Sayles & Natixis
Loomis Sayles: Reaping the rewards of a long-term, high-conviction approach
The Growth Equity Strategies Team at Loomis Sayles, an affiliate of Natixis Investment Managers, demonstrates that patience, discipline and conviction result in consistent, peer-leading risk-adjusted compounding over cycles.
-
GMO CEO sees growing interest in liquid alternatives
‘I don’t have enough liquid alternatives on my platform’ – is a common confession from heads of manager research at different wealth platforms in Asia, according to GMO CEO Scott Hayward.
-
JPMAM rebrands Campbell Global to J.P. Morgan Natural Capital
J.P. Morgan Natural Capital is part of J.P. Morgan Asset Management’s $326bn alternative investment business.
-
Federated Hermes partners with Conduit Digital on tokenized money market fund in Apac
The alliance with Conduit announcement represents Federated Hermes’ first digital assets initiative in Apac.
-
Partners Group reshuffles leadership with new co-CEOs
Current CEO David Layton will transition to chief investment officer to focus solely on investments.
-
Artemis’s Snowden: Should bond investors avoid the hyperscalers?
Head of fixed income explains why he prefers a software provider and data centre company.
The Gatekeepers In partnership with
-
Julius Baer’s Jeffrey Tam: Diversify equities with financials and biotech
Short-dated credit also offers a compelling middle ground between cash and the broader fixed income universe, Jeffrey Tam, head fund specialists, Hong Kong, Julius Baer tells FSA.
-
Metrobank Trust’s Ma. Cristina Gabaldon: DPM allows clients to focus on long-term financial goals
A core component of Metrobank Trust’s approach is global diversification, Ma. Cristina Gabaldon, head of investment of the investment management division, tells FSA.
-
Affin Bank’s Wong Kok Hong: Diversification remains the foundation of portfolio construction
The Malaysian firm has onboarded more covered call strategies for income generation, Affin Bank’s head of wealth investment advisory, Wong Kok Hong tells FSA.
-
Indosuez’s Qian Su recommends alts for diversification in pro-risk stance
Head of investment management Asia, Qian Su, has also added equity hedge funds with systematic strategies in the US and Asia and also natural resources funds.
-
Lombard Odier’s Jack Siu backs convertibles for protection and performance
Lombard Odier’s “total wealth approach” also includes private market exposure, the firm’s head of discretionary portfolio management, Asia, Jack Siu, tells FSA.
-
BNP Paribas WM’s Adrien Lalau: A personalised approach is essential
Building strong relationships with clients is crucial to providing tailored recommendations, says Adrien Lalau, head of investment funds advisory, Asia at BNP Paribas Wealth Management
Research
-
3 biotech funds that more than doubled in 14 months
FSA highlights three actively managed biotechnology equity strategies that have more than doubled in value over the recent 14-month period.
Upcoming events
Fund Selector Asia is hosting our flagship Investment Forums as well as bespoke events and Roundtables in Hong Kong, Malaysia, Philippines, Singapore, and Thailand.